Eisai Canada company information, Employees & Contact Information

Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC Eisai

New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease Eisai

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia Biogen

Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China Eisai

Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone ACN Newswire

Eisai Rated “A”, the Highest Rating by CDP in the Categories of Climate Change and Water Security Eisai

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Early Alzheimer’s Disease in Mexico Biogen

Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment Eisai

Digital Asset Library Eisai

The First 80 Years | Eisai Co., Ltd. Eisai

EISAI ESTABLISHES THEORIA TECHNOLOGIES CO., LTD., A NEW DIGITAL BUSINESS COMPANY TO BUILD A DEMENTIA ECOSYSTEM Eisai

“LEQEMBI® Intravenous Infusion” (Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20 Eisai

EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN | News Release：2022 Eisai

Corporate Venture Capital Eisai

Eisai’s Efforts on Global Health ― An Interview of Scientists Working on Drug Discovery Eisai

Initiatives for Improving Access to Medicines Eisai

ANTIEPILEPTIC DRUG FYCOMPA® INJECTION FORMULATION LAUNCHED IN JAPAN Eisai

Production and Logistics (Demand Chain Systems) Eisai

Compliance and Risk Management Eisai

Alzheimer's Disease Treatment The Aricept R&D Story Eisai

Dementia Eisai

Discovering the Hidden Challenges: Understanding the Needs of the Alzheimer’s Disease Community Eisai

Message from Top Management Eisai

EISAI LAUNCHES REDESIGNED CORPORATE WEBSITE Eisai

To Develop Japan’s First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research Eisai

Biomarker research for early diagnosis of Alzheimer's Eisai

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status Biogen

Chapter 6 Breaking into the Top 20 Worldwide Eisai

EISAI INC.'S U.S. HEADQUARTERS EARNS THREE KEY BUILDING CERTIFICATIONS PR Newswire

Eisai co-establishes “Global Health Innovative Technology Fund,” Japan's first public–private partnership to eliminate infectious disease in developing countries | Research & Development for Improving Access to Medicines Eisai

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA Biogen

Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease At Clinical Trials On Alzheimer’s Disease (Ctad) Conference Biogen

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union Biogen

Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership PR Newswire

Hackensack Meridian Health and Eisai Inc. Join Forces to Support the Expansion of Alzheimer's Disease Detection and Services for Patients PR Newswire

Eisai Inc. Deepens Its Commitment to Alzheimer's Disease with Key Executive Appointments PR Newswire

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel Biogen

Eisai Inc. Announces the Appointment of Dr. Luca Dezzani as Vice President, U.S. Medical Affairs, Oncology Business Group PR Newswire

Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders PR Newswire

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China Biogen

Incidence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population Wiley

Eisai and Biogen Announce Approval of LEQEMBI® for Maintenance Dosing in Alzheimer's Disease Treatment in China Quiver Quantitative

Patrick Coyle Appointed Vice President and Chief Financial Officer of Eisai Inc. PR Newswire

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease Biogen

Eisai Enters Agreement to Transfer Its Research Triangle Park Campus to Biogen PR Newswire

Adriana Herrera Appointed Senior Vice President, Americas Commercial Oncology at Eisai Inc. PR Newswire

Eisai Appoints Dr. Andree Amelsberg as VP, U.S. Medical Affairs, Oncology Business Group citybiz

Rebecca Jolley appointed Senior Vice President Americas Commercial, Oncology Business Group at Eisai Inc. PR Newswire

Eisai Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day PR Newswire

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium FinancialContent

Eisai Limited Bolsters Canadian Operations with Major Mississauga Expansion PR Newswire Canada